8/5/2013

The FDA has postponed its decision for three months on GlaxoSmithKline's type 2 diabetes drug albiglutide, saying now that a decision will come on April 15. The approval process in Europe for the once-weekly, injectable GLP-1 drug is moving ahead on schedule.

Full Story:
Reuters

Related Summaries